The effects of dasatinib combined with conventional chemotherapy on the outcome of induction therapy in children with CBF-AML (NCMCs-AML01-CBFtki)

The effects of dasatinib combined with conventional chemotherapy on the outcome of induction therapy in children with CBF-AML

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IIR-17013615

Enrollment

Unknown

Registered

2017-11-30

Start date

2017-11-20

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CBF-AML

Interventions

Experimental group:dasatinib

Control group:placebo

Eligibility

Sex/Gender

All

Age

No minimum to 18 Years

Inclusion criteria

Inclusion criteria: 1. Aged <18 years of new diagnosed AML; 2. AML-ETO or CBFB-MYH11 fusion gene positive; 3. All patients need to have informed consent signed by parents or legal guardian before enrollment into the study.

Exclusion criteria

Exclusion criteria: 1. Secondary (post-MDS) AML; 2. Secondary (medicine) AML; 3. Down syndrome-AML; 4. With serious organ dysfunction; 5. With congenital immunodeficiency disease, organ transplantation history or secondary tumor.

Design outcomes

Primary

Measure	Time frame
induction therapy CR rate;	—

Secondary

Measure	Time frame
safety;	—

Countries

China

Contacts

Public ContactShen Shuhong

Shanghai Jiaotong University School of Medicine Affiliated Shanghai Children's Medical Center

shenshuhong@scmc.com.cn+86 18930830638

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026